Skip to main content
MyDeficiencies

Gabapentin

Gabapentinoid, anticonvulsant / alpha-2-delta calcium channel ligand

Also sold as Neurontin.

Recognized as Gabapentin.

Researched 9/3/2026

Evidence summary

Qualifying findings
0
Interactions and timing
1
Searched, nothing found
11
Verified cited sources
1 of 1
Analyze another medication Medication directory

Overview

Gabapentinoid, anticonvulsant / alpha-2-delta calcium channel ligand. Recognized as Gabapentin.

Researched 9/3/2026 · Adversarial review ran: 4 confirmed, 4 scope corrections, 2 rejected.

1 of 1 cited sources were confirmed to exist as described. That check confirms the source is real, not that it supports the claim.

Findings for this medication

Research about this medication, graded for how strongly each finding can be attributed to it. Nothing here describes your own levels.

No nutrient reaches red for gabapentin. Like several other drugs in this series, gabapentin is not appreciably metabolized, does not inhibit or induce any of the major CYP450 enzymes at clinically relevant concentrations, and is excreted by the kidney essentially unchanged, so it carries none of the classical hepatic machinery that lets some drugs accelerate nutrient catabolism. The one real, drug-specific signal this review found is bounded rather than clear-cut: a large mixed-anticonvulsant cohort found gabapentin among the drugs associated with lower folate and B12, in contrast to levetiracetam and benzodiazepines, which showed no association at all in the same study. But most of that cohort was on combination therapy, not gabapentin alone, and no mechanism has been established for why a drug with no hepatic metabolism would produce this effect, so it grades orange, not red.

gabapentinoid (α2δ calcium-channel ligand) · ATC N03AX12 · also sold as Neurontin and Gralise and Horizant (enacarbil prodrug) · reviewed September 5, 2026, expanded September 10, 2026. This describes research about the medication. It does not say anything about your own levels or health.

How to read the evidence grades

These colours describe how strongly a finding can be attributed to the medication in the research. They are not a severity score and they say nothing about your own health.

Grades describe how strongly a finding can be attributed to Gabapentin in the research — not how common it is, how serious it would be, and not anything about you personally.

Red — Severe
two or more independent Tier A sources, this drug in the cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence.
Orange — Moderate
at least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit.
Yellow — Low
mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction.
Not graded — disclosed evidence gap
Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result.Source definition: Not gradeable under the rules above because nothing has been measured. Published as a documented gap, never as reassurance that there is no effect.

What the research found

Folate & vitamin B12

Orange — Moderate

See study details

A large mixed-anticonvulsant cohort found gabapentin among the drugs associated with lower folate and B12, but most gabapentin-exposed patients in that cohort were also on other anticonvulsants, and no mechanism has been established.

Full detail and limits

What the grade means here: at least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit. ORANGE · bounded by cohort composition

Limits on what this shows

  • Key negative / null findings: Levetiracetam and benzodiazepines in the same cohort showed no folate/B12 association, which argues the effect isn't universal to all antiseizure drugs and somewhat strengthens confidence in the comparison, but does not by itself supply a mechanism for gabapentin.
  • At-risk subgroups: Patients on combination anticonvulsant therapy (the majority of this cohort), where isolating gabapentin's independent contribution from co-administered drugs is not possible with the data located; longer-duration treatment generally.

Regulatory status

Neither folate nor B12 is named in the gabapentin prescribing information.

Population evidence

Linnebank et al., Ann Neurol 2011: 2,900 epilepsy patients (958 on monotherapy, 1,772 on combination anticonvulsant therapy) plus 200 healthy controls. Most anticonvulsants, including newer agents, were associated with reduced folate and/or B12; gabapentin was named among the drugs showing this association. Levetiracetam and benzodiazepines, studied in the same cohort, showed no such association.

Mechanism

Not established. The classic mechanism for anticonvulsant-associated folate/B12 changes is hepatic enzyme induction altering folate metabolism, well documented for phenytoin, carbamazepine, and phenobarbital. Gabapentin has no hepatic metabolism and induces no CYP450 enzyme, so that pathway cannot explain an effect here if one exists; no alternative mechanism was identified in this review.

Counter-evidence held on record

Combination-therapy dominance in the cohort (1,772 of 2,730 treated patients) limits how confidently this can be attributed to gabapentin monotherapy specifically. The absence of any known mechanism for a non-metabolized, non-enzyme-inducing drug is itself a reason for caution, not confirmation. Present as an observed association in a mixed-drug population, not as a mechanism-confirmed, monotherapy-isolated finding. Do not describe this the way an enzyme-induction-mediated depletion would be described, because that is not what this is.

Phosphate & vitamin D activation

Yellow — Low

See study details

A laboratory hypothesis ties gabapentin's own receptor target to impaired phosphate handling and vitamin D activation, but it has been shown only in treated cells and knockout mice, never in gabapentin-treated humans.

Full detail and limits

What the grade means here: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. YELLOW · mechanistic, no human data

Limits on what this shows

  • Key negative / null findings: None located; this is an unconfirmed hypothesis rather than a contradicted one.
  • At-risk subgroups: Not defined by human data. Observational literature separately associates gabapentinoid use with increased fracture incidence, but fracture is a clinical outcome, not a nutrient measurement, and is noted here only as the background that motivated this hypothesis, not as evidence for it.

Regulatory status

Not named in the gabapentin label.

Population evidence

Wheeler, Noonan, Thompson & White, INSIGHT 2019: gabapentin-treated murine mesenchymal progenitor cells showed reduced mineralization and reduced expression of mineralization-related genes. Mice lacking the α2δ-1 subunit, gabapentin's own binding target, independently showed reduced bone mineral density and osteomalacia. The authors propose phosphate wasting or impaired 1,25-vitamin D activation downstream of α2δ targeting as the connecting mechanism. No gabapentin-treated human data was presented.

Mechanism

Present in a lab model, specific to gabapentin's actual pharmacological target rather than borrowed from a different drug class, which distinguishes it from the debunked vitamin D claim below. Not confirmed as operating in gabapentin-treated humans.

Counter-evidence held on record

None located; the gap is an absence of human confirmation, not a contradiction. Do not conflate this with the vitamin D claim in the fails-verification table below; they are two different, unrelated proposed mechanisms. This one is gabapentin-specific but confirmed only in lab models; the other is borrowed from a different drug class and does not apply to gabapentin at all.

Antacids & mineral supplements

Yellow — Low

See study details

Aluminum- and magnesium-hydroxide antacids reduce gabapentin's own bioavailability by about 20%; this is the mineral affecting the drug, not the drug depleting the mineral.

Full detail and limits

What the grade means here: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. YELLOW · direction reversed, timing interaction

Limits on what this shows

  • Key negative / null findings: Not applicable; this is a documented label interaction, not a status claim requiring a null-result search.
  • At-risk subgroups: Patients taking calcium, magnesium, or aluminum-containing antacids or mineral supplements at the same time as gabapentin.

Regulatory status

Documented directly in the gabapentin label's Drug Interactions section (Tier A).

Population evidence

FDA label: aluminum/magnesium-hydroxide antacids reduce gabapentin bioavailability by approximately 20%; dosing gabapentin at least 2 hours after the antacid reduces this to approximately 5%.

Mechanism

Named: altered gastric conditions and/or direct interference with gabapentin's own intestinal absorption via its saturable transport system, not a mineral-depletion mechanism at all.

Counter-evidence held on record

Not applicable; the label is direct on this point. Never present this as "gabapentin depletes minerals." It is the reverse: minerals reduce gabapentin's own absorption. The actionable guidance is a timing separation of at least 2 hours, not a supplement recommendation.

The five body-system areas

Each finding is counted once, in a single area. Where a study is mentioned in a second area it is context only.

Mitochondrial Burden

Each finding below is counted once, in this area only.

Mitochondrial burden

Not graded — disclosed evidence gap

See study details

No study located measures gabapentin's effect on mitochondrial function, morphology, or biogenesis in a way this review could verify. This is not gradeable, not a reassurance, and not a red flag.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. UNGRADED · evidence gap

Limits on what this shows

  • Why no grade: No Tier B or Tier C evidence supporting a mitochondrial-burden concern was found, and no circulating consumer claim naming gabapentin and mitochondria or cellular energy was located either (a related "CoQ10 as adjuvant therapy to gabapentin" study exists but is a combination-therapy efficacy question, not a depletion claim, and should not be read as one). Both conditions for UNGRADED are met.
  • At-risk subgroups: Not defined; no data exists to define one.

Regulatory status

Mitochondrial function is not named in the gabapentin label.

Population evidence

None found that this review could open and verify. Two review-level sources that plausibly cover antiepileptic drugs and mitochondrial toxicity as a class were located (a 2017 Epilepsy Research paper and a 2016 review chapter) but every mirror attempted (PubMed, ScienceDirect, Springer, ResearchGate) returned a CAPTCHA, 403, or 429 block; whether gabapentin was even in scope for either could not be confirmed, so neither is used to support any claim here.

Mechanism

None confirmed. One candidate mechanism was checked and excluded: an in vitro study (gabapentin used directly, cell-culture model) found gabapentin suppresses cell proliferation through a pathway independent of cytosolic branched-chain amino acid transferase 1 (BCAT1), the one energy-metabolism-adjacent enzyme tested; full text was blocked, so this is reported only to the extent the paper's own title states it, as a mechanism ruled out rather than confirmed.

Counter-evidence held on record

A study titled "Gabapentin lactam induces neurodevelopmental deficits via calcium-mitochondria-ROS cascade" was located and deliberately excluded: gabapentin lactam is a distinct chemical transformation/degradation product of gabapentin, studied here in zebrafish as an environmental contaminant, not the administered drug studied in patients. Citing it as evidence about gabapentin the medication would be a cohort-substitution error. Do not present this as "gabapentin is safe for mitochondria." No study confirms that either. State plainly that this has not been studied in a way this review could verify.

Oxidative Stress

Each finding below is counted once, in this area only.

Oxidative stress markers

Yellow — Low

See study details

The one human study located that directly measured oxidative stress markers in gabapentin-treated patients found no significant difference from other treatment groups, and the animal literature located leans toward gabapentin reducing, not increasing, oxidative stress in injury models. This is graded yellow as a context flag, not as a theoretical harm.

Full detail and limits

What the grade means here: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. YELLOW · reassuring context, not a deficit

Limits on what this shows

  • Key negative / null findings: The human study's null result (TAS, TOS, PON1, OSI all non-significant across groups, including versus treatment-naive controls) is the most load-bearing finding in this entry and is reported here in full per this dossier's counter-evidence rule, not omitted because it fails to support a claim.
  • At-risk subgroups: None identified. No subgroup in the located evidence showed a gabapentin-associated increase in oxidative stress markers.

Regulatory status

No oxidative-stress marker is named in the gabapentin label.

Population evidence

Human, Tier A: an observational study of 63 type 2 diabetic polyneuropathy patients split into treatment-naive, alpha-lipoic-acid-only, gabapentin-only (n=19, 900–3,200 mg daily, ≥6 weeks), and combination groups measured total antioxidant status (TAS), total oxidant status (TOS), paraoxonase-1 (PON1), and oxidative stress index (OSI). No statistically significant difference was found among the four groups (p>0.05); gabapentin showed no measurable effect on any of the four markers. Animal, Tier B, gabapentin used directly: a rat toxic-demyelination model and a diabetic rat retina model are both titled and indexed as finding gabapentin reduces ("attenuates") oxidative stress markers in the injured tissue, consistent with an antioxidant rather than a pro-oxidant direction; full text of both could not be independently opened for this review (see Sources), so no specific marker values from either are cited here beyond what their own titles assert.

Mechanism

No mechanism for gabapentin-induced oxidative stress was located at any tier. The animal literature instead proposes an antioxidant/neuroprotective mechanism (independent of gabapentin's α2δ pain-signaling target) in specific injury models, which is a different question from whether gabapentin causes oxidative stress in a person with no such injury; this dossier does not extrapolate a protective finding in an injury model into a general safety claim either.

Counter-evidence held on record

The gabapentin-only arm of the diabetic polyneuropathy study is the strongest available evidence and it is null. Two animal studies point toward a protective association rather than a harmful one; both are cited by title only because full text could not be opened, so their direction is reported cautiously and their specific numbers are not cited at all. Do not present this entry as "gabapentin may cause oxidative stress." The evidence located argues the opposite. This entry exists to document that the question was asked and searched, and what was found, not to seed a concern the data does not support.

Copper and Iron Balance

Copper and iron are assessed separately. Nothing here is counted twice.

Iron

Not graded — disclosed evidence gap

See study details

No study, and no circulating consumer claim, ties gabapentin to iron status. This is a clean evidence gap, distinct from the existing folate/B12 finding, which involves a different anemia mechanism entirely.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. UNGRADED · evidence gap

Limits on what this shows

  • Why no grade: No Tier B or Tier C evidence and no circulating claim were located. Both conditions for UNGRADED are met.
  • At-risk subgroups: Not defined; no data exists to define one.

Regulatory status

Iron is not named in the gabapentin label. The label's only mineral-related content is the antacid/absorption interaction already graded yellow above.

Population evidence

None located. A professional drug-interaction check against iron sulfate returned no documented interaction in either direction.

Mechanism

None plausible was identified. Gabapentin is absorbed via a saturable L-amino-acid transporter (system L) in the small bowel, not the divalent-metal transporter (DMT1) pathway iron uses, so there is no shared-transporter basis for a chelation or competitive-absorption mechanism, unlike the aluminum/magnesium antacid interaction, which works through a different route (gastric conditions and gabapentin's own transporter, not iron's).

Counter-evidence held on record

Classic antiepileptic-drug trace-element literature (serum zinc/copper studies in epileptic children) was checked for an iron arm and for gabapentin's presence; the verified cohort in the source this review could open studied sodium valproate, carbamazepine, phenytoin, clonazepam, and levetiracetam, not gabapentin, and did not measure iron. It is named here as searched and excluded, not extrapolated. Do not conflate this with the existing folate/B12 orange entry. B12/folate deficiency causes macrocytic anemia through a cobalamin/folate pathway; iron deficiency causes a mechanistically distinct microcytic anemia. Finding one does not imply or rule out the other.

Gut Microbiome Risk

Each finding below is counted once, in this area only.

Gut microbiome risk

Not graded — disclosed evidence gap

See study details

No study measuring gabapentin's effect on gut microbiome composition was located, for gabapentin or for the gabapentinoid class generally, and no circulating consumer claim names gabapentin among microbiome-disrupting medications.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. UNGRADED · evidence gap

Limits on what this shows

  • Why no grade: No Tier B or Tier C evidence and no circulating claim were located, despite a search that also checked whether gabapentin appears on consumer "medications that cause leaky gut" lists (it does not, on the one such list opened directly; antibiotics, NSAIDs, oral contraceptives, steroids, and acid-reducing drugs were listed instead). Both conditions for UNGRADED are met. Per this dossier's confounding-by-indication rule, any future study finding a microbiome difference in gabapentin-treated patients would also need to rule out the neuropathic pain, seizure, or anxiety condition being treated, and the reduced mobility or altered diet that can accompany it, as the actual driver, not gabapentin itself.
  • At-risk subgroups: Not defined; no data exists to define one.

Regulatory status

Not addressed in the gabapentin label beyond standard gastrointestinal adverse-effect listings (diarrhea, constipation, dyspepsia) common to many CNS-active drugs.

Population evidence

None located. A Mendelian-randomization study of common pain medications and gut microbiota composition (UK Biobank / MiBioGen data) explicitly limited its analgesic classes to NSAIDs, salicylic acid, opioids, and anilides; gabapentin and the gabapentinoid class were outside its scope, confirmed on direct review, not assumed. A narrative review of psychotropic drug classes and the microbiome ("Psychotropics and the Microbiome") was opened directly and does not mention gabapentin or gabapentinoids anywhere in its drug-class coverage.

Mechanism

None confirmed by any study. A plausible but unstudied mechanism exists in principle: gabapentin's absorption is saturable and falls as dose rises, so a larger fraction of a higher oral dose reaches the colon unabsorbed than a lower dose, and gabapentin causes dose-related constipation or diarrhea in a minority of patients per the label, either of which could in principle alter transit time or deliver drug directly to colonic bacteria. No source located has tested this; it is named here as what would need to be studied, not as evidence.

Counter-evidence held on record

An animal study on microglial activity and gut microbiota in a neuropathic-pain model was located but concerns pain physiology and microglia, not a gabapentinoid drug exposure, and was excluded as not on point. Do not present this as "gabapentin does not affect the microbiome." Absence of evidence is not evidence of absence; state plainly that this has not been studied.

Oxygen and ATP Output

Oxygen delivery and ATP production are assessed separately. Nothing here is counted twice.

Oxygen delivery & utilization

Not graded — disclosed evidence gap

See study details

No nutrient-mediated oxygen-carriage deficit specific to gabapentin was located. The one well-documented, serious gabapentin risk in this territory, FDA-warned respiratory depression, is the drug's own pharmacological effect on breathing drive, not a nutrient-mediated finding, and is not graded here.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. UNGRADED · evidence gap

Limits on what this shows

  • Why no grade: No Tier B or Tier C nutrient-mediated evidence and no circulating consumer claim describing gabapentin as impairing nutrient-based oxygen delivery were located. Both conditions for UNGRADED are met for the nutrient question; the respiratory-depression finding itself is real but out of scope for a nutrient grade by definition.
  • At-risk subgroups: For the (non-nutrient) respiratory-depression risk specifically: concurrent opioid or CNS-depressant use, COPD or other respiratory disease, and older adults. Not a nutrient-status subgroup.

Regulatory status

The gabapentin label and a December 2019 FDA drug safety communication warn that gabapentinoids can cause serious, sometimes fatal, respiratory depression, chiefly through additive CNS depression when combined with opioids or other CNS depressants, and in patients with COPD or other reduced respiratory function; the FDA's own review over 2012–2017 identified 49 case reports and 12 deaths, nearly all in patients with these risk factors. This is a real, Tier A, drug-specific finding, and Hard Rule 1 of this dossier's governance requires it be named as gabapentin's own known adverse mechanism, not relabeled as a nutrient-deficiency finding.

Population evidence

No study located measures gabapentin's effect on hemoglobin, oxygen saturation physiology, or nutrient-dependent oxygen-carrying capacity as distinct from the CNS respiratory-drive effect above.

Mechanism

The respiratory-depression mechanism is CNS/brainstem suppression of breathing drive, consistent with gabapentin's sedative class effects; it does not run through hemoglobin, iron, or any nutrient pathway, so it cannot be filed as an oxygen-delivery nutrient finding regardless of its clinical seriousness.

Counter-evidence held on record

The existing orange folate/B12 entry above describes a mechanism (megaloblastic anemia) that, if present, would itself impair oxygen-carrying capacity. That is the folate/B12 entry's finding, already graded there; it is referenced here as context, not re-graded as an independent oxygen-delivery deficit. Never describe FDA-warned respiratory depression as a nutrient deficiency, a supplement gap, or something a supplement could address. It is a pharmacological effect of the drug itself and belongs in prescribing guidance, not a nutrient panel.

ATP production

Not graded — disclosed evidence gap

See study details

No study located measures gabapentin's effect on cellular ATP synthesis, and no circulating consumer claim was found either. Graded separately from mitochondrial burden above, as this dossier's governance requires, even though the two share most of the same underlying search.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. UNGRADED · evidence gap

Limits on what this shows

  • Why no grade: No Tier B or Tier C evidence and no circulating claim were located. Both conditions for UNGRADED are met.
  • At-risk subgroups: Not defined; no data exists to define one.

Regulatory status

ATP or cellular energy output is not named in the gabapentin label.

Population evidence

None located that this review could verify. A study on coenzyme Q10 as adjuvant therapy to gabapentin for diabetic neuropathy was located by title; it examines whether adding CoQ10 improves gabapentin's own treatment response, a combination-therapy efficacy question, not whether gabapentin lowers CoQ10 or ATP output, and should not be read as depletion evidence.

Mechanism

None confirmed. See the mitochondrial-burden entry above for the one candidate mechanism checked (BCAT1) and ruled out by title; it is referenced here, not re-counted as separate evidence for ATP specifically.

Counter-evidence held on record

This entry and the mitochondrial-burden entry above are graded independently per this dossier's rules, but they draw on the same underlying search and the same excluded sources (gabapentin lactam, the BCAT1 study); neither entry's evidence is used twice to make two findings look more substantiated than one search actually supports. Do not present this as "gabapentin is energy-neutral" or safe for mitochondrial function. State plainly that ATP output has not been studied for this drug.

Claims checked and not supported

These circulate online for this medication. They are listed here only so they can be answered, never as findings, and they are not graded.

A claim with no supporting evidence is not necessarily disproven. Where evidence actually argues against a claim, that is stated below.

  • Copper — already addressed as a failed claim

    Where it comes from: WHITE · see fails-verification table

    Why it fails: Copper is graded white, not ungraded: a specific circulating consumer claim exists and was already rebutted in this dossier's fails-verification table. See the expanded row added there rather than a duplicate entry here. Placed in the index for completeness alongside the other four new categories; the substantive grading, facts, and rebuttal are recorded once, in the fails-verification table, to avoid the double counting this dossier's overlap-control rule prohibits.

  • Vitamin D (via "long-term anticonvulsant use interferes with vitamin D activity")

    Where it comes from: Suzy Cohen, "How to Properly Take Gabapentin and Restore 5 Lost Nutrients" (suzycohen.com); repeated on similar consumer sites.

    Why it fails: The mechanism this claim relies on, hepatic enzyme induction accelerating vitamin D catabolism, is well established only for phenytoin, carbamazepine, phenobarbital, and similar enzyme-inducing anticonvulsants. Gabapentin's own label confirms no appreciable metabolism and no CYP450 induction, so this pathway cannot apply to gabapentin. This is a class-label error: "anticonvulsant" swept in a drug with entirely different pharmacology. (A separate, gabapentin-specific vitamin D/phosphate hypothesis is addressed above at yellow; do not confuse the two.)

  • Calcium

    Where it comes from: Same source. States gabapentin will "somehow reduce calcium via the drug mugging effect."

    Why it fails: No citation of any kind is offered for this claim, and its own justification is the phrase "somehow," which is not a mechanism. "Drug mugging" is marketing language this dossier does not adopt. No supporting study, human or animal, was located.

  • Vitamin A

    Where it comes from: Same source.

    Why it fails: No citation offered; no supporting study located at any tier.

  • Copper & zinc

    Where it comes from: Same source, which links to an unrelated general-audience article on copper deficiency symptoms not connected to gabapentin.

    Why it fails: No gabapentin-specific or anticonvulsant-class study was located for either mineral. The cited link does not itself discuss gabapentin.

  • Biotin (bundled into vague "B complex" claims)

    Where it comes from: Same source and similar consumer lists that group B12, folate, and biotin together.

    Why it fails: The real signal located in this review (folate and B12, graded orange above) does not extend to biotin; no biotin-specific data for gabapentin or anticonvulsants generally was found.

  • Copper, specifically (expanded, September 10, 2026)

    Where it comes from: Same Suzy Cohen source as the bundled copper/zinc row above; this row documents a dedicated copper-specific search performed for this review's Copper category, not a new independent claim.

    Why it fails: No Tier A, B, or C evidence for a gabapentin-copper relationship was located anywhere in an expanded search. Chemistry papers describing zinc and copper "ternary complexes" of gabapentin are crystal-engineering and coordination-chemistry studies synthesizing metal-gabapentin salts for materials research; they document that gabapentin can chelate copper ions in a test tube, not that it alters copper status in a treated person, and are not physiological evidence. A professional drug-interaction check against copper found no documented interaction in either direction. Classic antiepileptic trace-element literature (serum copper/zinc changes with carbamazepine and valproate) does not include gabapentin in its cohort and, per this dossier's class-extrapolation rule, does not extrapolate to it anyway: the proposed mechanism in that literature involves hepatic enzyme induction and metal-binding protein changes, machinery gabapentin's own label confirms it does not have, the same reasoning already applied to the vitamin D claim above.

What the research says is worth watching

General information from the medication label and the studies above. It is not personal medical advice, and any change belongs with your prescriber.

  • Folate & B12

    Lab · combination therapy Consider baseline and periodic checks for patients on gabapentin as part of combination anticonvulsant therapy, particularly with longer treatment duration, per the Linnebank 2011 cohort finding above.

  • Antacids & mineral supplements

    Timing separation Take aluminum/magnesium-hydroxide antacids at least 2 hours apart from gabapentin dosing to avoid reducing its absorption by up to 20%.

  • Renal function

    Lab · dosing Gabapentin is cleared renally, unchanged; dose must be reduced in renal impairment. Monitor CrCl per prescriber guidance, especially in older adults.

  • Take with food

    Dosing logistics High-fat meals increase absorption; this is a drug-efficacy consideration from the label, not a nutrient-separation issue.

  • Phosphate / vitamin D testing

    No action indicated The receptor-mediated hypothesis above is lab-only; not a basis for routine testing in this dossier.

  • Opioid co-prescription

    Cross-drug flag Label-documented: morphine increases gabapentin AUC ~44%, hydrocodone ~14%. Not a nutrient issue, but relevant for polypharmacy patients and worth noting alongside any nutrient-focused review.

All references used above
  1. FDA / DailyMed. Gabapentin tablets, prescribing information. — Regulatory label, DailyMed setid 0ce53f62-1738-43f4-9a2e-c5dc42a91d09, revision May 2025. Clinical Pharmacology §12, Drug Interactions §7.
  2. Linnebank M, et al. Antiepileptic drugs interact with folate and vitamin B12 serum levels. — Ann Neurol. 2011. Observational cohort, n=2,900 epilepsy patients (958 monotherapy, 1,772 combination therapy) + 200 healthy controls. Gabapentin named among associated drugs; levetiracetam and benzodiazepines showed no association. Gabapentin in cohort. Precise per-drug effect size for gabapentin alone was not retrievable from the sources this review could access; reported qualitatively for that reason.
  3. Wheeler JA, Noonan ML, Thompson WR, White KE. Gabapentin targeting and bone mineralization defects: proposed mechanism for increased fracture risk in patients taking GBP-class anti-epileptic drugs. — INSIGHT, Vol. 2, August 2019. In vitro (gabapentin-treated murine mesenchymal progenitor cells) and animal (α2δ-1 knockout mice) study; gabapentin used directly in the in vitro portion. No human data.
  4. Suzy Cohen, RPh. "How to Properly Take Gabapentin and Restore 5 Lost Nutrients." — Consumer health content (Tier D). Cited only to document the origin of the calcium, vitamin A, copper/zinc, B-complex, and vitamin D claims audited above; not used as evidentiary support for any graded entry.
  5. Author(s) not independently confirmed. The efficacy of alpha-lipoic acid and/or gabapentin on the oxidant-antioxidant system in patients with diabetic polyneuropathy. — International Journal of Research in Medical Sciences (IJRMS). Human observational study, n=63 type 2 diabetic polyneuropathy patients in four groups (treatment-naive, alpha-lipoic acid only, gabapentin only n=19 at 900–3,200 mg/day ≥6 weeks, combination). Measured TAS, TOS, PON1, OSI; no statistically significant between-group difference (p>0.05). Gabapentin directly in cohort.
  6. Author(s) not independently confirmed. The effect of gabapentin on oxidative stress in a model of toxic demyelination in rat brain. — J Basic Clin Physiol Pharmacol. 2012. Animal (rat), gabapentin used directly per title/abstract listing.Could not independently verify full text (PubMed and ResearchGate mirrors both blocked by CAPTCHA/429 on repeated attempts). Cited only by title; no marker values or effect sizes taken from it.
  7. Author(s) not independently confirmed. Gabapentin Attenuates Oxidative Stress and Apoptosis in the Diabetic Rat Retina. — Neurotoxicity Research (Springer). Animal (rat), gabapentin used directly per title.Could not independently verify full text (fetch blocked/rate-limited on repeated attempts). Cited only by title; no marker values or effect sizes taken from it.
  8. Author(s) not independently confirmed. Toxicity of gabapentin-lactam on the early developmental stage of zebrafish ( Danio rerio ). — Environmental toxicology study, verified via AGRIS record. Gabapentin-lactam is explicitly described as a transformation product of gabapentin, not the parent drug; found to be more toxic than gabapentin itself to zebrafish embryos, with effects on nervous-system, antioxidant, and immune biomarkers at concentrations as low as 0.01 µg/L. Cited here only to document why this compound was excluded from the mitochondrial-burden entry above; it is not evidence about administered gabapentin.
  9. Author(s) not independently confirmed. Gabapentin Can Suppress Cell Proliferation Independent of the Cytosolic Branched-Chain Amino Acid Transferase 1 (BCAT1). — Biochemistry (ACS), 2018. In vitro, gabapentin used directly per title.Could not independently verify full text (403/429 on repeated attempts). Cited only to the extent its own title states a conclusion (BCAT1-independent mechanism); no data or effect sizes taken from it.
  10. U.S. Pharmacist staff. FDA Issues Warning About Breathing Difficulties With Gabapentinoid Use. — Trade-press summary of FDA Drug Safety Communication, December 2019, verified directly. Reports FDA review of case reports (49 over 2012–2017, including 12 deaths, nearly all with concurrent CNS depressants or respiratory risk factors), mechanism (additive CNS depression), and risk factors (opioids, other CNS depressants, COPD, older age). The FDA's own safety-communication page at fda.gov could not be loaded directly (404 on the URL located); this trade-press summary was opened and verified in its place.
  11. Drugs.com. Gabapentin and Zinc drug interaction check (professional). — Professional interaction database, verified directly: no interaction found in either direction.
  12. Drugs.com. Gabapentin and Iron Sulfate drug interaction check (professional). — Professional interaction database, verified directly: no interaction found in either direction.
  13. Author(s) not independently confirmed. Serum levels of zinc and copper in epileptic children during long-term therapy with anticonvulsants. — Human observational study, n=90 epileptic children, verified directly. Drugs studied: sodium valproate (n=27), carbamazepine (n=12), and combination therapy including phenytoin, clonazepam, and levetiracetam; carbamazepine reduced serum zinc and raised serum copper more than valproate. Gabapentin was confirmed not present in this cohort.Cohort confirmed to exclude gabapentin; used only to show classic-AED trace-element literature does not cover this drug and, per this dossier's mechanism reasoning, would not extrapolate to it regardless.
  14. Author(s) not independently confirmed. Assessing the impact of common pain medications on gut microbiota composition and metabolites: insights from a Mendelian randomization study. — Journal of Medical Microbiology. Mendelian-randomization design using UK Biobank (n=466,457) and MiBioGen (n=18,340) summary genetic data, verified directly. Analgesic classes assessed: NSAIDs, salicylic acid, opioids, and anilides. Gabapentin and gabapentinoids confirmed outside the study's scope.Gabapentin confirmed not assessed; cited only to document that this search was performed and came back empty for this drug.
  15. Author(s) not independently confirmed. Psychotropics and the Microbiome: a Chamber of Secrets… — Psychopharmacology (Springer), 2019. Narrative review of antipsychotics, antidepressants, antianxiety drugs, anticonvulsants/mood stabilizers, opioids, drugs of abuse, alcohol, nicotine, and xanthines, verified directly for gabapentin coverage: gabapentin and gabapentinoids are not mentioned anywhere in the reviewed content.
  16. Amy Myers MD (site). 5 Medications that Can Cause Leaky Gut. — Consumer health content (Tier D), verified directly. Lists antibiotics, NSAIDs, oral contraceptives, steroids, and acid-reducing drugs; gabapentin, anticonvulsants, and neuropathy medications are not mentioned. Cited only to document that a dedicated search for a gut-microbiome consumer claim came back empty for this drug.
  17. Author(s) not independently confirmed. Potential Positive Effects using Coenzyme Q10 Supplement as Adjuvant Therapy to Gabapentin for Managing Diabetic Neuropathy. — Study design not independently confirmed beyond its title.Could not independently verify full text (429 on repeated attempts). Cited only by title, to show this is an adjuvant-therapy efficacy question rather than a depletion claim; no data taken from it.
  18. Author(s) not independently confirmed. Zinc and copper ternary complexes of gabapentin with neurotransmitters (two related papers). — Coordination/crystal-engineering chemistry (ScienceDirect), titles and abstracts reviewed via search listing only, full text not opened. Synthetic chemistry describing gabapentin-metal salt complexation in vitro for materials characterization, not a physiological or clinical study of copper or zinc status.Full text not opened; treated as non-physiological chemistry evidence only, per the Copper fails-verification row above, not cited for any clinical claim.

Interactions and timing

How this medication and a nutrient affect each other's absorption, handling or timing. This is not depletion.

Medication and nutrient interaction

Magnesium (as magnesium oxide antacid)

exact entity

Interaction and timing

An interaction between Gabapentin and Magnesium (as magnesium oxide antacid) was reported, affecting absorption, handling or timing. No change in nutrient status is claimed here. This is an interaction between Gabapentin and Magnesium (as magnesium oxide antacid), not a measured change in your Magnesium (as magnesium oxide antacid) status.

1 cited source and detail

How this medication and this nutrient affect each other's absorption, handling or timing. This is not the same as depletion.

Relationship:
decreased
Outcome measured:
Medication and nutrient interaction
Study population:
human studies
Agreement:
1 supporting, 0 contradicting

What was measured: An interaction between Gabapentin and Magnesium (as magnesium oxide antacid) was reported, affecting absorption, handling or timing. No change in nutrient status is claimed here.

Proposed mechanism: Proposed reduced intestinal absorption of gabapentin due to interaction with magnesium in the gut, potentially involving the saturable amino acid transporter used for gabapentin absorption. A mechanism explains how an effect could occur. It is not itself a measured clinical outcome.

1 of 1 cited sources were checked and found to support this specific claim. A source existing is not the same as a source supporting the claim.

Why it is here: This is an absorption, binding or timing interaction between the medication and the nutrient, not a measured depletion.

Searched, no supporting evidence found

These relationships were searched for in this research run and no supporting evidence was found. Absence of evidence is not evidence of absence.

Zinc

unresolved scope

Searched, no supporting evidence found

No gabapentin-specific human study measuring zinc levels was found in this research run.

What was searched

We looked for this relationship and did not find supporting evidence. Absence of evidence is not evidence of absence.

Why it is here: No retrievable source was found for this relationship.

Copper

unresolved scope

Searched, no supporting evidence found

No gabapentin-specific human study measuring copper levels was found in this research run; a case report on a patient using multiple drugs including gabapentin is not attributable to gabapentin alone.

What was searched

We looked for this relationship and did not find supporting evidence. Absence of evidence is not evidence of absence.

Why it is here: No retrievable source was found for this relationship.

Zinc/copper balance

unresolved scope

Searched, no supporting evidence found

No gabapentin-specific study of zinc to copper ratio was found in this research run.

What was searched

We looked for this relationship and did not find supporting evidence. Absence of evidence is not evidence of absence.

Why it is here: No retrievable source was found for this relationship.

Vitamin A

unresolved scope

Searched, no supporting evidence found

No gabapentin-specific human study measuring vitamin A levels was found in this research run.

What was searched

We looked for this relationship and did not find supporting evidence. Absence of evidence is not evidence of absence.

Why it is here: No retrievable source was found for this relationship.

Ceruloplasmin

unresolved scope

Searched, no supporting evidence found

No study measuring ceruloplasmin in gabapentin-treated patients was found in this research run.

What was searched

We looked for this relationship and did not find supporting evidence. Absence of evidence is not evidence of absence.

Why it is here: No retrievable source was found for this relationship.

Show the remaining 6 searched relationships

Vitamin B6

unresolved scope

Searched, no supporting evidence found

No gabapentin-specific human study measuring vitamin B6 levels was found in this research run.

What was searched

We looked for this relationship and did not find supporting evidence. Absence of evidence is not evidence of absence.

Why it is here: No retrievable source was found for this relationship.

Vitamin B12

unresolved scope

Searched, no supporting evidence found

No gabapentin-specific human study measuring vitamin B12 levels was found in this research run.

What was searched

We looked for this relationship and did not find supporting evidence. Absence of evidence is not evidence of absence.

Why it is here: No retrievable source was found for this relationship.

Biotin

unresolved scope

Searched, no supporting evidence found

No gabapentin-specific interaction or depletion evidence for biotin was found in this research run.

What was searched

We looked for this relationship and did not find supporting evidence. Absence of evidence is not evidence of absence.

Why it is here: No retrievable source was found for this relationship.

Calcium

unresolved scope

Searched, no supporting evidence found

No human study measuring serum calcium as an outcome of gabapentin therapy was found in this research run.

What was searched

We looked for this relationship and did not find supporting evidence. Absence of evidence is not evidence of absence.

Why it is here: No retrievable source was found for this relationship.

Mitochondrial-related biological context

unresolved scope

Searched, no supporting evidence found

No human study measuring a specific mitochondrial nutrient or cofactor change with gabapentin was found in this research run.

What was searched

We looked for this relationship and did not find supporting evidence. Absence of evidence is not evidence of absence.

Why it is here: No retrievable source was found for this relationship.

Vitamin B12 / folate / biotin depletion

unresolved scope

Searched, no supporting evidence found

No reliable primary evidence was found that gabapentin specifically depletes B12, folate, or biotin. The one retrieved human study on AED-related B-vitamin status explicitly excluded gabapentin from its studied cohort. The search also surfaced numerous commercial wellness-blog claims asserting this relationship without verifiable primary citations; those were rejected as non-qualifying sources.

What was searched

We looked for this relationship and did not find supporting evidence. Absence of evidence is not evidence of absence.

Why it is here: Searched in this research run (WebSearch (general literature); Epilepsy & Behavior article (Mintzer et al. 2012) retrieved via Jefferson Digital Commons open-access repository); no qualifying Gabapentin-specific evidence was identified.

Evidence limitations

What this cannot tell you

  • This is automated research that has not yet been reviewed by a person. It is not MyDeficiencies published knowledge, it is not medical advice, and it may be incomplete or wrong. It has been added to our editorial review queue.
  • This batch found no exact-medication human evidence establishing that gabapentin changes zinc, copper, zinc/copper ratio or vitamin A status.
  • Much of the circulating popular claim content conflates gabapentin with other anticonvulsants (phenytoin, phenobarbital, valproic acid) studied mainly in pediatric epilepsy populations.
All research limitations for this run
  • Case report evidence is anecdotal, involves polypharmacy, and cannot establish causation for gabapentin specifically.
  • Absence of evidence is not evidence of absence; this reflects the current retrievable literature only.
  • Much retrievable evidence for this medication is class-wide (anticonvulsants generally) rather than gabapentin-specific, and this packet has attempted to keep those distinct.
  • Secondary consumer health sources were used only for claim discovery and were traced to primary sources where possible; several popular claims could not be substantiated and were rejected.
  • Sample sizes in the directly relevant pharmacokinetic and pyridoxine studies are small.
  • This packet covers only Vitamin B12, Calcium, Biotin, and Mitochondrial-related biological context per batch 3 of 3 scope restriction.
  • No exact-medication randomized controlled human trials were found measuring vitamin B12 or biotin status with gabapentin.
  • Calcium and bone findings rely heavily on animal and mechanistic data with internal contradictions.
  • Mitochondrial context is supported only by in vitro enzyme assays, high-concentration cell culture work, and a narrative review, not direct human biomarker studies.
  • 20 of 27 cited sources could not be confirmed to exist as described. Claims resting only on those sources are withheld.
  • Provider output was capped/truncated multiple times during drafting; some structured content was reconstructed in a separate serialization-only turn.
  • Several cited sources are unreachable or absent per existence check and cannot be treated as verified evidence.
  • Most positive-leaning items rely on animal, in vitro, or class-level (multi-drug cohort) evidence rather than exact-medication human data.
  • Negative findings reflect only the searches actually run and do not establish that no relationship exists.
  • 8 of 11 sources that were confirmed to exist were not confirmed to support the specific claim they were attached to. Existence is not support, and those claims are withheld.
  • Every critical error the review reported was traced to a specific item and that item was withheld. Unrelated findings that independently pass every check were not suppressed by it.
  • No direct human evidence measuring a nutrient endpoint in people taking Gabapentin was found in this run. That is a statement about what we found, not a statement that no effect exists.
  • Search was not exhaustive; absence of evidence is not proof of no relationship.
  • Search reflects public/web-search discoverable literature, not a full institutional database (e.g. Embase, Micromedex) search; absence of evidence is not proof of no relationship.
  • One taurine-transporter paper (PMID 26631583) could not be retrieved to confirm whether gabapentin was among the tested compounds. Other potential nutrient dimensions remain unresearched.

Medication Dossier - every finding carries its own evidence grade, sources and limitations. Educational information only, not medical advice. Educational information only. Not medical advice, diagnosis or treatment. Talk to your prescriber or pharmacist before changing any medication or supplement.

Sources

Only sources attached to information shown above are listed here.

  • Impact of concomitant antacid administration on gabapentin plasma exposure and oral bioavailability in healthy adult subjects

    Randomized crossover pharmacokinetic study · human study

    PMID 22240839· identifier confirmed to exist (PMID)

    https://pubmed.ncbi.nlm.nih.gov/22240839/
  • Existence of a source and support for a claim are checked separately. A confirmed identifier means the record is real, not that it supports the statement it is cited for.

Questions for your clinician

These are conversation prompts, not findings about you.

  • Could Gabapentin affect any nutrients over time in my situation?
  • Are there symptoms or risk factors that would make further evaluation appropriate?
  • Could diet, other medications, or health conditions affect this relationship?
  • Would laboratory testing be clinically appropriate for me?
  • Are there medication or supplement interactions I should understand?

Review status

Human review

Each medication dossier states the evidence grade, sources and limitations of every finding. This is educational information, not medical advice, and not a certification or endorsement by any medical body.

Checking your medications and reading the medication dossiers is free. A complete saved report is $29, paid once.

Derived from acceptance run artifacts/ke2-gabapentin-goldstandard.json (a01aede0605c).